$6.43
2.23% yesterday
Nasdaq, Oct 09, 10:00 pm CET
ISIN
US29970R1059
Symbol
EVAX

Evaxion Biotech A/S - ADR Stock price

$6.43
+3.63 129.64% 1M
+5.10 383.46% 6M
+2.20 52.12% YTD
-6.97 52.01% 1Y
-134.82 95.45% 3Y
-3.57 35.70% 5Y
-3.57 35.70% 10Y
-3.57 35.70% 20Y
Nasdaq, Closing price Thu, Oct 09 2025
+0.14 2.23%
ISIN
US29970R1059
Symbol
EVAX
Industry

Key metrics

Basic
Market capitalization
$36.1m
Enterprise Value
$32.7m
Net debt
positive
Cash
$14.8m
Shares outstanding
315.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.4 | 27.9
EV/Sales
10.3 | 25.2
EV/FCF
negative
P/B
5.8
Financial Health
Equity Ratio
-13.2%
Return on Equity
639.7%
ROCE
-81.5%
ROIC
-449.7%
Debt/Equity
1.8
Financials (TTM | estimate)
Revenue
$3.2m | $1.3m
EBITDA
- | $-5.1m
EBIT
$-14.0m | $-15.8m
Net Income
$-12.0m | $-907.4m
Free Cash Flow
$-11.7m
Growth (TTM | estimate)
Revenue
1,035.7% | -61.3%
EBITDA
- | 63.9%
EBIT
26.9% | -7.4%
Net Income
21.2% | -8,484.5%
Free Cash Flow
24.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -394.1%
EBIT
-439.6%
Net
-377.1% | -70,122.2%
Free Cash Flow
-367.7%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
3.2%
Employees
46
Rev per Employee
$70.0k
Show more

Is Evaxion Biotech A/S - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,998 stocks worldwide.

Evaxion Biotech A/S - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

Buy
88%
Hold
13%

Financial data from Evaxion Biotech A/S - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3.18 3.18
1,036% 1,036%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.95 7.95
8% 8%
250%
- Research and Development Expense 9.19 9.19
14% 14%
289%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
27% 27%
-439%
Net Profit -12 -12
21% 21%
-377%

In millions USD.

Don't miss a Thing! We will send you all news about Evaxion Biotech A/S - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evaxion Biotech A/S - ADR Stock News

Neutral
GlobeNewsWire
one day ago
COPENHAGEN, Denmark, October 8, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is launching a significant improvement of its already leading AI-platform, AI-Immunology™, with a new automated vaccine design module.
Neutral
GlobeNewsWire
7 days ago
COPENHAGEN, Denmark, October 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor November 5-9, 2025. Designed with Evaxion's AI-Immunolo...
Positive
24/7 Wall Street
15 days ago
Shares of clinical-stage pharmaceutical company, Plus Therapeutics, are up about 31% on a volume spike of 216.4 million
More Evaxion Biotech A/S - ADR News

Company Profile

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Christian Kanstrup
Employees 46
Founded 2008
Website evaxion.ai

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today